Effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia

Journal of Shanghai Jiaotong University (Medical Science)

Volumn 31, Issue 6, 2011, Pages 809-812

  Shen, Jian ^a   Chen, Jian Hua ^a   Yu, Qi Wei ^a   Shen, Jie ^a   Sun, Peng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Benign prostatic hyperplasia; Terazosin; Tolterodine

Indexed keywords

TERAZOSIN; TOLTERODINE;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MICTURITION; MONOTHERAPY; NOCTURNAL ENURESIS; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; UNSPECIFIED SIDE EFFECT; URINE FLOW RATE; URINE INCONTINENCE; URINE VOLUME;

EID: 79959854993     PISSN: 16748115     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1674-8115.2011.06.28     Document Type: Article

References (13)

1. Narayan P, Leper H. Long-term, open-label, phase H multicenter study of tamsuLsin in benign prostatic hyperplasia [J]. Urology, 2001, 57(3): 466- 470.
2. Bouchelouche K, Andersen L, Alvarez S, et al. Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction: effect of the alphalA and alphal D-adrenergic receptor antagonist tamsulosin[J]. J Urol, 2005, 173(2); 657 -661.
3. Price DT, Schwinn DA, Lomasney JW, et al. Identification, quantification and localization of mBNA for three distinct alpha 1 adrenergic receptor snbtypes in human prostate [J] - J Urol, 1993, 150 (2 Pt 1): 546 -551.
4. Schwinn DA, Michelotti CA. Alphal-adrenoceptor receptors in the lower miliary tract and vascular bed; potential role for the alphal d inftype in filling symptoms and effects of ageing on vascular expression [J]. BJU Int, 2000, 85(Snppl2): 6-11.
5. Matsumoto S, Uemura H. Examination of the mechanism of ameliorating effect of alpha 1 -blocker on storage symptoms associated with benign prostatic hyperplasia [J]. Hinyofcika Kiyo, 2008, 54(6); 453-456.
6. Roehrborn CG, Boyle P, Nickel JC, et al Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia [J]. Urology, 2002, 60(3); 434-441.
7. Crawford ED. Management of lower urinary tract symptoms sugges-tive of benign prostatic hyperplasia: the central role of the patient risk prafile[J]. BJU Int, 2005, 95(Suppl4): 1-5.
8. Yoshida A, Kageyama A, FujinoT, et al. Epub 2010 Aug 16.Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis [J]. Urology, 2010, 76 (4): 1017.
9. Kap lan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder; a randomized controlled trial [J]. JAMA, 2006, 296(19): 2319-2328.
10. Ho CH, Chang TC, Lin HH, et al Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms [J]. J Fonnos Med Assoc, 2010, 109(10): 702-708.
11. Oelke M, Kuczyk MA, Herrmann TR. Pharmacological treatment of benign prostatic hyperplasia[J]. Urologe A, 2009, 48(11); 1365-1375.
12. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction; a prospective, randomized, controlled multicenter study[J]. J Urol, 2005, 174(4 Ptl): 1334-1338.
13. Wyman JF, Klutke C, Burgio K, et al. Effects of combined behavioral intervention and tolterodine on patient-reported outcomes [J]. Can J Urol, 2010, 17(4): 5283-5290